TISLELIZUMAB
Information current as at: 1 June 2026
PBAC meeting date: July 2026
Submission Details
- Brand name:
-
- Tevimbra®
- Form and strength:
-
- Solution concentrate for I.V. infusion 100 mg in 10 ml
- Solution concentrate for I.V. infusion 150 mg in 15 ml
- Submission sponsor:
- BEONE MEDICINES AUS PTY LTD
- Condition/indication:
(therapeutic use) -
- Gastro-oesophageal cancer
- Listing requested:
- To request listing of tislelizumab for advanced or metastatic gastro-oesophageal cancer such that patients can be administered treatment with 150 mg once every two weeks (Q2W) and 300 mg once every four weeks (Q4W) as an alternative to the current dosing regimen of 200 mg once every 3 weeks (Q3W). The submission also seeks listing of a new 150 mg vial form of tislelizumab.
- Funding program:
- PBS Section 100 (Efficient Funding of Chemotherapy)
- Request authority level:
- Authority Required (STREAMLINED)
- PBAC Submission type:
- New PBS listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
1243
Page last updated
31 May 2026
v.9.19